Broader label could lift limp Xofluza sales

24 November 2020
2020_roche_big

Roche (ROG: SIX) subsidiary Genentech has successfully broadened the US label for Xofluza (baloxavir marboxil), to include treatment to prevent influenza after contact with an infected person.

Xofluza is the first single-dose flu medicine approved for post-exposure prophylaxis, in people 12 years of age and older.

The efficacy of Xofluza for this purpose was demonstrated by the Phase III BLOCKSTONE study, data from which were published in The New England Journal of Medicine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology